JBPHF (Jacobio Pharmaceuticals Group Co) Other Current Assets: $5.81 Mil (As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.34
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Other Current Assets?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Other Current Assets is $5.81 Mil as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.34. The stock has 6 warning signs investors should review.

Jacobio Pharmaceuticals Group Co's other current assets for the quarter that ended in Dec. 2025 was $5.81 Mil.

Jacobio Pharmaceuticals Group Co's quarterly other current assets declined from Dec. 2024 ($0.65 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($5.81Mil).

Jacobio Pharmaceuticals Group Co's annual other current assets declined from Dec. 2023 ($2.01 Mil) to Dec. 2024 ($0.65 Mil) increased from Dec. 2024 ($0.65 Mil) to Dec. 2025 ($5.81 Mil).


Jacobio Pharmaceuticals Group Co Other Current Assets Related Terms


Jacobio Pharmaceuticals Group Co Other Current Assets Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Other Current Assets Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial 2.34 2.16 2.01 0.65 5.81

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 0.65 0.65 0.00 5.81
JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $5.81 Mil mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Other Current Assets of $5.81 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Jacobio Pharmaceuticals Group Co.
Is Jacobio Pharmaceuticals Group Co's Other Current Assets too high?
Jacobio Pharmaceuticals Group Co's current Other Current Assets is $5.81 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Other Current Assets compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Other Current Assets of $5.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Jacobio Pharmaceuticals Group Co. Jacobio Pharmaceuticals Group Co's current Other Current Assets is $5.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Other Current Assets of $5.81 Mil. The stock's GF Value™ is $0.34, compared to a current price of $0.87 — trading 155.2% above its estimated fair value. The current Other Current Assets is $5.81 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Other Current Assets is $5.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 155.2% above its estimated GF Value™ of $0.34.

Key valuation signals for JBPHF:

  • Other Current Assets: $5.81 Mil
  • GF Value™: $0.34 vs. price of $0.87 (155.2% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.34
GF Value